Immunohistochemically demonstrated metallothionein expression in malignant melanoma

B. Zelger, A. Hittmair, M. Schir, C. Ofner, P. O. Fritsch, W. Bocker, B. Jasani, K. W. Schmid

Research output: Contribution to journalArticle

94 Citations (Scopus)

Abstract

Metallothioneins are ubiquitous proteins with a high affinity for heavy metal ions, e.g. zinc, copper and cadmium. Experimentally, metallothionein over-expression in cell lines derived from a variety of cancers has been associated with resistance to anticancer drugs and irradiation therapy. Using a monoclonal antibody (E9) to metallothionein we investigated immunoreactive expression in routinely fixed and paraffin-embedded tissue from 63 cases of malignant melanoma and 13 secondary deposits. Whereas a variety of cells in normal skin showed metallothionein expression, all forms of benign naevi studied wre uniformly negative. In contrast 13/30 'thin' (≤1.5 mm; 0.7 ± 0.4), 25/29 'thick' malignant melanoma (>1.5 mm; 5.5 ± 3.9) and 12/13 metastases were positive. Six patients with thin and 19 with thick melanoma with metallothionein expression died during a mean observation period of 6.4 ± 1.8 and 3.6 ± 2.5 years, respectively, their survival distribution function analyses giving statistically significant results for both the vertical tumour thickness (P <0.0001) and metallothionein expression (P <0.0001). These immunohistochemical results, based on routinely processed paraffin-embedded tissue, suggest that metallothionein expression in malignant melanoma is significantly associated with progressive disease and might therefore be a useful prognostic indicator.

Original languageEnglish
Pages (from-to)257-263
Number of pages7
JournalHistopathology
Volume23
Issue number3
Publication statusPublished - 1993

Fingerprint

Metallothionein
Melanoma
Paraffin
Heavy Ions
Nevus
Heavy Metals
Cadmium
Zinc
Copper
Neoplasms
Monoclonal Antibodies
Observation
Neoplasm Metastasis
Drug Therapy
Cell Line
Skin
Survival
Proteins

Keywords

  • Immunohistochemistry
  • Malignant melanoma
  • Metallothionein
  • Normal skin

ASJC Scopus subject areas

  • Cell Biology
  • Anatomy
  • Pathology and Forensic Medicine

Cite this

Zelger, B., Hittmair, A., Schir, M., Ofner, C., Fritsch, P. O., Bocker, W., ... Schmid, K. W. (1993). Immunohistochemically demonstrated metallothionein expression in malignant melanoma. Histopathology, 23(3), 257-263.

Immunohistochemically demonstrated metallothionein expression in malignant melanoma. / Zelger, B.; Hittmair, A.; Schir, M.; Ofner, C.; Fritsch, P. O.; Bocker, W.; Jasani, B.; Schmid, K. W.

In: Histopathology, Vol. 23, No. 3, 1993, p. 257-263.

Research output: Contribution to journalArticle

Zelger, B, Hittmair, A, Schir, M, Ofner, C, Fritsch, PO, Bocker, W, Jasani, B & Schmid, KW 1993, 'Immunohistochemically demonstrated metallothionein expression in malignant melanoma', Histopathology, vol. 23, no. 3, pp. 257-263.
Zelger B, Hittmair A, Schir M, Ofner C, Fritsch PO, Bocker W et al. Immunohistochemically demonstrated metallothionein expression in malignant melanoma. Histopathology. 1993;23(3):257-263.
Zelger, B. ; Hittmair, A. ; Schir, M. ; Ofner, C. ; Fritsch, P. O. ; Bocker, W. ; Jasani, B. ; Schmid, K. W. / Immunohistochemically demonstrated metallothionein expression in malignant melanoma. In: Histopathology. 1993 ; Vol. 23, No. 3. pp. 257-263.
@article{7718f29bb4de447984756a84161e691d,
title = "Immunohistochemically demonstrated metallothionein expression in malignant melanoma",
abstract = "Metallothioneins are ubiquitous proteins with a high affinity for heavy metal ions, e.g. zinc, copper and cadmium. Experimentally, metallothionein over-expression in cell lines derived from a variety of cancers has been associated with resistance to anticancer drugs and irradiation therapy. Using a monoclonal antibody (E9) to metallothionein we investigated immunoreactive expression in routinely fixed and paraffin-embedded tissue from 63 cases of malignant melanoma and 13 secondary deposits. Whereas a variety of cells in normal skin showed metallothionein expression, all forms of benign naevi studied wre uniformly negative. In contrast 13/30 'thin' (≤1.5 mm; 0.7 ± 0.4), 25/29 'thick' malignant melanoma (>1.5 mm; 5.5 ± 3.9) and 12/13 metastases were positive. Six patients with thin and 19 with thick melanoma with metallothionein expression died during a mean observation period of 6.4 ± 1.8 and 3.6 ± 2.5 years, respectively, their survival distribution function analyses giving statistically significant results for both the vertical tumour thickness (P <0.0001) and metallothionein expression (P <0.0001). These immunohistochemical results, based on routinely processed paraffin-embedded tissue, suggest that metallothionein expression in malignant melanoma is significantly associated with progressive disease and might therefore be a useful prognostic indicator.",
keywords = "Immunohistochemistry, Malignant melanoma, Metallothionein, Normal skin",
author = "B. Zelger and A. Hittmair and M. Schir and C. Ofner and Fritsch, {P. O.} and W. Bocker and B. Jasani and Schmid, {K. W.}",
year = "1993",
language = "English",
volume = "23",
pages = "257--263",
journal = "Histopathology",
issn = "0309-0167",
publisher = "Wiley Blackwell",
number = "3",

}

TY - JOUR

T1 - Immunohistochemically demonstrated metallothionein expression in malignant melanoma

AU - Zelger, B.

AU - Hittmair, A.

AU - Schir, M.

AU - Ofner, C.

AU - Fritsch, P. O.

AU - Bocker, W.

AU - Jasani, B.

AU - Schmid, K. W.

PY - 1993

Y1 - 1993

N2 - Metallothioneins are ubiquitous proteins with a high affinity for heavy metal ions, e.g. zinc, copper and cadmium. Experimentally, metallothionein over-expression in cell lines derived from a variety of cancers has been associated with resistance to anticancer drugs and irradiation therapy. Using a monoclonal antibody (E9) to metallothionein we investigated immunoreactive expression in routinely fixed and paraffin-embedded tissue from 63 cases of malignant melanoma and 13 secondary deposits. Whereas a variety of cells in normal skin showed metallothionein expression, all forms of benign naevi studied wre uniformly negative. In contrast 13/30 'thin' (≤1.5 mm; 0.7 ± 0.4), 25/29 'thick' malignant melanoma (>1.5 mm; 5.5 ± 3.9) and 12/13 metastases were positive. Six patients with thin and 19 with thick melanoma with metallothionein expression died during a mean observation period of 6.4 ± 1.8 and 3.6 ± 2.5 years, respectively, their survival distribution function analyses giving statistically significant results for both the vertical tumour thickness (P <0.0001) and metallothionein expression (P <0.0001). These immunohistochemical results, based on routinely processed paraffin-embedded tissue, suggest that metallothionein expression in malignant melanoma is significantly associated with progressive disease and might therefore be a useful prognostic indicator.

AB - Metallothioneins are ubiquitous proteins with a high affinity for heavy metal ions, e.g. zinc, copper and cadmium. Experimentally, metallothionein over-expression in cell lines derived from a variety of cancers has been associated with resistance to anticancer drugs and irradiation therapy. Using a monoclonal antibody (E9) to metallothionein we investigated immunoreactive expression in routinely fixed and paraffin-embedded tissue from 63 cases of malignant melanoma and 13 secondary deposits. Whereas a variety of cells in normal skin showed metallothionein expression, all forms of benign naevi studied wre uniformly negative. In contrast 13/30 'thin' (≤1.5 mm; 0.7 ± 0.4), 25/29 'thick' malignant melanoma (>1.5 mm; 5.5 ± 3.9) and 12/13 metastases were positive. Six patients with thin and 19 with thick melanoma with metallothionein expression died during a mean observation period of 6.4 ± 1.8 and 3.6 ± 2.5 years, respectively, their survival distribution function analyses giving statistically significant results for both the vertical tumour thickness (P <0.0001) and metallothionein expression (P <0.0001). These immunohistochemical results, based on routinely processed paraffin-embedded tissue, suggest that metallothionein expression in malignant melanoma is significantly associated with progressive disease and might therefore be a useful prognostic indicator.

KW - Immunohistochemistry

KW - Malignant melanoma

KW - Metallothionein

KW - Normal skin

UR - http://www.scopus.com/inward/record.url?scp=0027306140&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0027306140&partnerID=8YFLogxK

M3 - Article

C2 - 8225244

AN - SCOPUS:0027306140

VL - 23

SP - 257

EP - 263

JO - Histopathology

JF - Histopathology

SN - 0309-0167

IS - 3

ER -